Premium
P3‐090: Change in the connectivity of multidimensional outcomes in a clinical trial of rosiglitazone for Alzheimer's disease
Author(s) -
Mitnitski Arnold,
Zeng An,
Gold Michael,
Rockwood Kenneth
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.1530
Subject(s) - placebo , rosiglitazone , medicine , disease , clinical trial , cognition , psychiatry , pathology , receptor , alternative medicine
Understanding disease progression in dementia trials relies chiefly on multidimensional measures, such as the Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog), NeuroPsychiatric Inventory (NPI) and the quality of life measure EQ-5D. Typically, mean changes in each measure are compared statistically. Recent work has suggested that change in the degree of connectivity between items which make up these scores can reflect underlying disease processes. We evaluated change in connectivity in patients treated with rosiglitazone, which does not impact disease progression. Figure 1. Connectivity Graphs at Baseline